GYRE THERAPEUTICS, INC.
GYRE · XNASCIK 1124105fmd_05540E69XQFAP0H1K9E1R4EJ2FManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 1 | 0 | – | 21 | 7 | 102 | 113 | 106 | 117 |
| Cost of revenue | – | – | – | – | – | – | 5 | 5 | 4 | 5 |
| Net interest income | – | – | – | – | – | – | 1 | 1 | 2 | 2 |
| Gross profit | – | – | – | – | – | – | 97 | 109 | 102 | 111 |
| Research and development | 12 | 13 | 21 | 44 | 53 | 69 | 17 | 14 | 12 | 14 |
| Selling, general and administrative | – | – | – | – | – | – | 72 | 76 | 74 | 86 |
| Total operating expenses | 21 | 23 | 34 | 57 | 78 | 95 | 88 | 176 | 90 | 105 |
| Operating income | (20) | (22) | (34) | (57) | (57) | (88) | 9 | (67) | 16 | 11 |
| Interest expense | – | – | – | – | – | – | – | – | – | – |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | 0 | (0) | 2 | (0) | (0) | (0) | – | (2) | (2) | (2) |
| Income before taxes | – | – | – | – | – | (88) | 9 | (77) | 23 | 14 |
| Income tax expense | – | – | – | – | – | – | 5 | 9 | 5 | 5 |
| Net income from continuing operations | – | – | – | – | – | – | 4 | (85) | 18 | 10 |
| Net income | (17) | (22) | (30) | (55) | (56) | (88) | 4 | (85) | 18 | 10 |
| Net income to common shareholders | (17) | (26) | (30) | (55) | (56) | – | 2 | (93) | 12 | 5 |